Anti-Coagulants - Mongolia

Mongolia

The Anti-Coagulants market in Mongolia is expected to achieve a revenue of US$1.56m by the year 2024.
It is projected to display a compound annual growth rate (CAGR 2024-2029) of 7.12%, leading to a market volume of US$2.20m by 2029.
Among all countries, United States is anticipated to generate the highest revenue of US$16,740.00m in 2024.
Despite the growing prevalence of cardiovascular diseases in Mongolia, the adoption of anti-coagulants remains relatively low due to limited access to healthcare facilities and lack of awareness among the population.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Mongolia has been experiencing steady growth over the past few years.

Customer preferences: Patients in Mongolia are increasingly opting for anticoagulants as a treatment option for various cardiovascular diseases. This is due to the convenience and ease of administration of these drugs, as well as their effectiveness in preventing blood clots.

Trends in the market: There has been a significant increase in the number of patients diagnosed with cardiovascular diseases in Mongolia, leading to a rise in demand for anticoagulants. Additionally, the government has been taking steps to improve healthcare infrastructure and increase access to medical treatments, further driving the growth of the anticoagulants market in the country. However, the market is still relatively small compared to other countries in the region.

Local special circumstances: One of the unique challenges faced by the anticoagulants market in Mongolia is the lack of awareness among the general population about the importance of cardiovascular health. This has led to many cases of cardiovascular diseases being diagnosed at a later stage, making treatment more difficult. Additionally, the cost of these drugs can be prohibitive for some patients, particularly those living in rural areas.

Underlying macroeconomic factors: Mongolia's economy has been growing steadily in recent years, driven by the mining sector. This has led to an increase in disposable income and a growing middle class, which has in turn led to an increase in demand for healthcare services. The government has also been investing in healthcare infrastructure, which has helped to improve access to medical treatments across the country. However, there are still challenges to be addressed, such as the high cost of medical treatments and the lack of awareness about cardiovascular health.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.